Galapagos에 대한 매도 수량은 투자자에게 Galapagos의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Galapagos (NASDAQ:GLPG) 주식, 공매도 수량 보고

Galapagos

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Analyst Color

Biotech

News

Downgrades

Health Care

General

GILD

GLPG

뱅크 오브 아메리카 증권(BofA)은 유럽 제약회사 갈라파고스 NV(NASDAQ:GLPG)을 하향 조정하며, 단기적인 촉매제 부족에 대해 언급했다.갈라파고스의 기업 가치는 지속적으로 낮은 15억 ~ 20억 달러 사이에서 유지되고 있으며, 이에 대해 애널리스트들은 즉각적이거나 중기적인 해결책을 기대하지 않고 있다.게다가 이 회사의 주요 프로그램은 차별화가 불분명하고 성장을 촉진할 중요한 촉매제가 부족한 혼잡한 시장에 진출하고 있다.

느린 파이프라인 진전으로 어려운 싸움을 하는 갈라파고스 평가 하향: 분석가

Galapagos NV - American Depositary Shares

Galapagos NV

Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is leveraging tonight&#8217;s boxing match between Mike Tyson and Jake Paul to <a href="https://www.benzinga.com/topic/streaming">bolster its live offerings</a>. 
The streaming service, which has been <a href="https://www.benzinga.com/general/sports/24/11/41985523/paul-vs-tyson-boxing-match-how-to-watch-betting-odds-what-the-stats-say-and-more">pushing into live sports content</a>, currently boasts more than 282 million global paid subscribers. Its ad-supported plan recently hit <a href="https://www.benzinga.com/media/24/11/41915397/netflix-reaches-70-million-users-on-ad-supported-plan-boosts-live-sports-ads">70 million subscribers</a>.
So far, Netflix has aired live comedy stand-ups, award shows, roasts and other special events. This is its inaugural boxing event.
Taking place at AT&amp;T Stadium in Dallas, the fight features a dramatic age gap. Tyson, 58, is a boxing legend known for his fierce power. His career record is 50 wins and six losses. Paul, 27, is a social media personality turned boxer beginning in 2020. He holds a 10-1 record with seven knockouts in his career. His lone loss came via a split decision to Tommy Fury in February 2023.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41985133/mike-tyson-on-psychedelics-the-toad-showed-me-god-and-it-changed-my-life">Mike Tyson On Psychedelics: &#8216;The Toad Showed Me God, And It Changed My Life&#8217;</a>
Tyson's last professional fight was in 2005, although he participated in a high-profile exhibition match in 2020 against Roy Jones Jr., which ended in a split draw. 
The buildup took an ugly turn when, during the weigh-in, Tyson slapped Paul. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Mike Tyson Slaps Jake Paul During Their Weigh-In" width="500" height="281" src="https://www.youtube.com/embed/7ImTO88zN-s?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
This real, officially sanctioned fight will be a significant test for both fighters, adding excitement to the streaming giant's growing sports portfolio.
Astronomical Cost To Attend: The celebrity fight promises huge profits. Per a <a href="http://Per a report by USA Today,">report</a> by USA Today, with 80,000 seats and VIP packages ranging from $5,000 to $25,000, the event is set to generate millions.
The exclusive MVP Owner&#8217;s Experience is valued at $2 million, and the fight will also stream live on Netflix, which will benefit from a significant audience. 
Tyson is estimated to earn $20 million, while Paul aims for $40 million.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41235640/netflix-to-become-default-choice-for-tv-movies-analyst-predicts-more-live-sports-pr">Netflix To Become &#8216;Default Choice&#8217; For TV, Movies? Analyst Predicts More Live Sports, Price Increases</a>
Betting Big: Per a <a href="https://nypost.com/2024/11/14/betting/jake-paul-bets-40-million-purse-that-hell-beat-mike-tyson/">report</a> by the NY Post, Paul has taken his confidence to the extreme, betting his entire $40 million purse on himself for his upcoming fight against Tyson.
During a pre-fight exchange, Paul accepted a challenge from Irish boxer Katie Taylor to wager his earnings, with Tyson favored to win.
While unlikely to see the bet come to fruition, Taylor, set to earn $6.1 million for her own fight against Amanda Serrano, stands at +650 odds for Tyson's victory.
In a bold move, <a href="https://www.vox.com/culture/385235/jake-paul-mike-tyson-fight-netflix">Paul offered Tyson $5 million</a> if he can last beyond four rounds. However, if Tyson fails, he must get a tattoo reading "I love Jake Paul." 
Tyson responded with his own counteroffer, demanding $20 million to agree to the challenge. This bet adds to the spectacle, further heightening the tension between the two fighters. It also fuels interest in the already highly anticipated event, blending high stakes with controversy.
Read Also: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41945418/netflix-stock-hit-a-new-all-time-high-whats-going-on">Netflix Stock Hit A New All-Time High: What&#8217;s Going On?</a></li>
</ul>
Image: Netflix

Entertainment

Sports Betting

Sports

NFLX

Netflix Streams Mike Tyson Vs. Jake Paul: The Fight Everyone's Talking About

Rumors

Trading Ideas

CELH

Watching Shares Of Celsius; Co. M&A Blog Mentioning The Company As A Potential Target For An Activist Investor

WIIM

JNPR

Juniper Networks shares are trading lower amid reports suggesting the DOJ is examining depositions of the company and Hewlett Packard Enterprise's executives and third-party CID responses.

The dust is beginning to settle from the 2024 election, and companies are starting to digest what a second Trump term means for business. On the campaign trail, Candidate Trump promised another round of tariffs on foreign goods, but it remains to be seen what promises actually translate into law once the administration comes to power.&nbsp;
Some companies like Steve Madden are attempting to get ahead of the curve by <a href="https://www.benzinga.com/24/11/41862692/steve-madden-announces-plans-to-move-production-to-avoid-trump-tariffs-but-theres-a-catch">moving production out of China now</a>, but others aren't as nimble and will likely bear the brunt of higher costs. Which public companies are likely to be hit hardest by tariff expansion? Here&#8217;s a list of 4 stocks you might want to consider selling before the next trade war salvo.
<h2 class="wp-block-heading">Methodology</h2>
Each company chosen for this list faces at least one of the following issues:
<ul>
<li>Reliance on imports, especially goods from China </li>
<li>Limited ability to pass higher costs onto customers </li>
<li>Lack of negotiating power with suppliers&nbsp;</li>
<li>Thin margins that could make it challenging to absorb costs </li>
</ul>
The retail industry is already bracing for higher costs. According to the National Retail Foundation, companies are preparing for these additional costs by raising prices on a variety of goods that could cost consumers between $46 billion and $76 billion in purchasing power. Retail will be a major theme amongst these stock picks, especially in areas where customers expect low prices and have substantial alternatives.
<h3 class="wp-block-heading">Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</h3>
Dell has been one of the market's biggest winners since the start of 2023. The company has re-entered the S&amp;P 500 and its stock price has soared from under $40 in March 2023 to over $130 as of this writing. The stock has pulled back a bit since hitting an all-time high of $179 in May, and more pain could be on the way if the proposed tariffs come to be.
Dell sells a variety of electronics, from computers and laptops to cloud and networking solutions. This line of electronics depends on affordable printed circuit boards (PCBs), capacitors, resistors, casings, and assembly operations, and much of this company infrastructure is located in China. Additional tariffs on these components could force Dell to either raise prices faster than customers see reasonable or relocate some of their production outside of China. Either solution could hamper future stock growth. Dell is currently rated a Buy, but the <a href="https://www.benzinga.com/quote/DELL/analyst-ratings">most recent analyst reports</a> put the consensus price target at $117, which is below the current market price.
<h3 class="wp-block-heading">Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>)</h3>
If you or your spouse are primary education teachers, you likely have spent a lot of time in Five Below looking for school supplies, affordable electronics, student rewards, and perhaps some candy for the lounge. The company sells a variety of merchandise at highly discounted prices, and many of its electronic products are imported from China.
Five Below gets hit from both sides in a potential tariff war. Not only is the company heavily reliant on Chinese imports, but its business model leaves very little room to raise prices. Customers who see higher prices at specialty retailers like Five Below may just take their business to higher-end competitors like Target Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>). Analysts currently rate FIVE stock as a Hold with an average price target of $129. However, the three most recent analyst reports (Truist, BofA Securities, and Evercore ISI) only had an average price target of $89, which is about where shares are currently trading. BofA analyst Lorraine Hutchinson <a href="https://www.cnbc.com/2024/11/06/trump-proposed-tariffs-consumer-prices.html">noted in her downgrade</a> that Five Below sources more than 20% of its products from China and lacks the pricing power to pass those costs onto consumers.
<h3 class="wp-block-heading">Lowe's Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>)</h3>
Another big winner from the past two years could be facing more headwinds if tariffs come to fruition. Lowe's has benefited from the home price boom as millions of Americans tapped their expanding home equity for upgrades and renovations following COVID. LOW shares shot from a pandemic low of $86 to $258 by December 2021 and recently made a new all-time high at $270 a few weeks ago. However, if we use history as a guide, Lowe's stock had a choppy ride during the first round of tariffs in 2017.
Lowe's sells high-end appliances like washing machines, dryers, refrigerators, water heaters, and other important (and imported) home goods. Not only will the company face higher costs on these expensive goods, but consumers who have already tapped chunks of home equity may put off new projects or rush to buy before the tariffs kick in. From 2017 to 2020, LOW shares exhibited high volatility with four different 15% corrections. With more tariffs on tap and consumers stretched thin, Lowe's profits could take a hit in the coming months. The company reports earnings on November 19 and investors will be looking for clues on how tariffs could affect its bottom line.
<h3 class="wp-block-heading">Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)</h3>
Another stock up big this year, and another company under pressure from the incoming administration. Walmart didn't suffer as much as the broader indices during the 2022 bear market, but the stock has roared to life in 2024. WMT shares are up over 60% year-to-date, including an eye-popping 41% in the last six months. The company has beaten analyst earnings expectations in each of the previous eight quarters as well.
In recent years, Walmart has sought to divest itself from China by moving some production to India, but Chinese imports still make up <a href="https://www.reuters.com/business/retail-consumer/walmart-shifts-india-china-cheaper-imports-2023-11-29/">about 60%</a> of the company's products. It's unlikely that much more production will be moved out of China by the time tariffs take effect, and Walmart doesn't have the supplier negotiating power that a company like Costco Wholesale Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) does. Additionally, Walmart's Every Day Low Price model runs on razor-thin margins. In July, Walmart reported a <a href="https://www.macrotrends.net/stocks/charts/WMT/walmart/net-profit-margin">net profit margin of 2.34%</a>. While not as low as some previous reports, Walmart has consistently seen its net margin drop below 3% since the first Trump administration, and the company may not have the pricing power to pass additional tariff costs onto its customers.
Take the guesswork out of investing with a handpicked portfolio of value stocks that consistently outperforms the S&amp;P 500. Invest in a proven, time-tested selection designed for long-term growth. <a href="https://www.benzinga.com/premium/ideas/perfect-portfolio/?utm_source=RD-1115">Click to get access now.</a>
Image via Shutterstock

Opinion

COST

DELL

FIVE

4 Stocks to Sell Before Trump's Tariffs Take Effect

Needham analyst Laura Martin maintains Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) with a Buy and raises the price target from $8.5 to $9.5.

Price Target

Analyst Ratings

NEXN

Needham Maintains Buy on Nexxen International, Raises Price Target to $9.5

In the current session, Aptiv Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) is trading at $53.09, after a 1.73% decrease. Over the past month, the stock decreased by 25.95%, and in the past year, by 34.77%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1731699923_0.png" alt="Past Year Chart" />

<h3>Comparing Aptiv P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Aptiv has a lower P/E than the aggregate P/E of 28.77 of the Automobile Components industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1731699923_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

APTV

Price Over Earnings Overview: Aptiv

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) with a Buy and maintains $33 price target.

Reiteration

PPBT

HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $33 Price Target

Legal

Watching Juniper Networks; Shares Move Lower As Traders Circulate Research Report Suggesting DOJ Examining Depositions Of Hewlett Packard Enterprise And Juniper Networks' Executives And Third-Party CID Responses, Preparing To Decide Case As Early As Next Week

<h3 class="wp-block-heading">Weed Is Not Legal In Florida But Medical Cannabis Retail Footprint Grows Nonetheless</h3>
RISE Dispensaries, a cannabis retail chain owned by Green Thumb Industries Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GTII#CSE">GTII</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTCQX">GTBIF</a>), opened RISE Dispensary Orlando on Good Homes Road on Friday, Nov. 8. Located at 725 Good Homes Road, the new West Orlando location expanded RISE Dispensaries' retail footprint in Florida to 21 locations and 99 nationwide.
Cannabis giant Curaleaf Holdings, Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CURA#TSX">CURA</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTCQX">CURLF</a>) opened a new medical dispensary in Miami in October. Curaleaf Miami Bird Road, located at 8868 SW Bird Rd. in Miami, brought the company's Florida store count to 66 locations, with 151 dispensaries total nationwide.
Trulieve Cannabis Corp. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/TRUL#CSE">TRUL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>), one of the biggest supporters of Amendment 3 which was rejected by Florida voters earlier this month and would have legalized recreational cannabis in the Sunshine State, additionally expanded its already substantial retail footprint statewide.
October store opening celebrations were held at:
<ul>
<li>Trulieve Bonita Springs South Tamiami, located at 28811 South Tamiami Trail, Unit 12, and Trulieve St. Augustine A1A, located at 3945 A1A South on Oct. 18;</li>
<li>Trulieve Orlando West Colonial, located at 7225 West Colonial Drive, Unit 100 on Oct. 25; and</li>
<li>Trulieve Lake Placid, located at 413 U.S. Highway 27, on Nov. 1.</li>
</ul>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">New Cannabis Stores In Six States And Canada</h3>
Illinois cannabis sales reached a major milestone in July, with sales surpassing $1 billion, as announced by Governor JB Pritzker‘s office. The burgeoning industry continues to grow by the day with new stores launching cannabis sales and events celebrating the plant. Stash Dispensaries recently announced the return of&nbsp;Sesh Haunted City, a special haunted house event to commemorate Sesh&#8217;s third anniversary.
C3 Industries, a multi-state cannabis company dedicated to crafting premium consumer experiences, recently opened High Profile Cannabis Shop Pineville at 35 Macadoodle Lane, its 9th retail location in Missouri and 29th nationwide.
Cannabis concept store Gotham held a grand opening event in October for its new Brooklyn, New York City location. The expansive 4,000-square-foot storefront is located in the heart of Williamsburg on Kent Avenue and South 2nd Street in The Refinery at Domino.
Sweetspot Farms, a new premium cannabis dispensary, is officially open at 111 High Ridge Rd. in Stamford, Connecticut, offering medical and recreational customers a modern and welcoming retail experience. Founded by two Stamford natives, Sweetspot aims to improve access to legal and regulated cannabis for qualified locals who depend on plant-based products for an improved quality of life.
SLO CAL Roots celebrated the grand opening of its third dispensary, Root One, in Guadalupe, California in October. Root One is the latest location from SLO CAL Roots, a Central Coast cannabis company founded in 2003 by local growers Austen Connella and Kristin Kordich.
Hashstoria, a cannabis dispensary co-founded by hip-hop icon Raekwon the Chef of Wu-Tang Clan fame, media personality Charlamagne Tha God, civil rights attorney Bakari Sellers and entrepreneur Jedd Canty hosted the official grand opening celebration in downtown Newark, New Jersey on Wednesday, Nov. 13. It's located at 799-805 Broad Street in the historic Four Corners district.
High Tide Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/HITI#TSXV">HITI</a>) (FSE: 2LYA) Canna Cabana retail cannabis store, located at 97 Bath Road, Kingston, Ontario, began selling recreational cannabis products and consumption accessories for adult use on Oct. 31. This opening marked the 186th Canna Cabana branded retail cannabis location in Canada, the 72nd in the province of Ontario, and the first in Kingston for the Canadian retail cannabis giant.

Cannabis

Entrepreneurship

Retail Sales

CSE:GTII

CSE:TRUL

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

GTII

HITI

TCNNF

TRUL

TSX:CURA

TSXV:HITI

Medical Marijuana Footprint Grows In Florida As Legalization Push Fizzles, And Other New Cannabis Stores

Needham analyst Laura Martin maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Buy and raises the price target from $110 to $130.

Needham Maintains Buy on Walt Disney, Raises Price Target to $130

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) with a Buy and maintains $10 price target.

CMPX

HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target

HC Wainwright &amp; Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) with a Buy and maintains $32 price target.

SGMT

HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target

HC Wainwright &amp; Co. analyst Yi Chen reiterates Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) with a Buy and maintains $15 price target.

KALA

HC Wainwright & Co. Reiterates Buy on Kala Bio, Maintains $15 Price Target

Keurig Dr Pepper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) has outperformed the market over the past 15 years by 2.32% on an annualized basis producing an average annual return of 14.04%. Currently, Keurig Dr Pepper has a market capitalization of $45.06 billion. 
Buying $1000 In KDP: If an investor had bought $1000 of KDP stock 15 years ago, it would be worth $7,196.06 today based on a price of $33.22 for KDP at the time of writing.
<h3>Keurig Dr Pepper's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699205_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Keurig Dr Pepper 15 Years Ago Would Be Worth This Much Today

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) has outperformed the market over the past 10 years by 6.46% on an annualized basis producing an average annual return of 17.48%. Currently, HCA Healthcare has a market capitalization of $87.70 billion. 
Buying $100 In HCA: If an investor had bought $100 of HCA stock 10 years ago, it would be worth $506.91 today based on a price of $339.83 for HCA at the time of writing.
<h3>HCA Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699201_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today

Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) has outperformed the market over the past 10 years by 18.87% on an annualized basis producing an average annual return of 29.89%. Currently, Fabrinet has a market capitalization of $9.04 billion. 
Buying $1000 In FN: If an investor had bought $1000 of FN stock 10 years ago, it would be worth $13,993.98 today based on a price of $249.31 for FN at the time of writing.
<h3>Fabrinet's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699196_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Fabrinet Stock In The Last 10 Years

First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) has outperformed the market over the past 20 years by 6.83% on an annualized basis producing an average annual return of 15.15%. Currently, First Citizens BancShares has a market capitalization of $30.11 billion. 
Buying $100 In FCNCA: If an investor had bought $100 of FCNCA stock 20 years ago, it would be worth $1,728.18 today based on a price of $2152.02 for FCNCA at the time of writing.
<h3>First Citizens BancShares's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699191_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FCNCA

If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,700 Today

HC Wainwright &amp; Co. analyst Edward White reiterates 60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) with a Neutral.

SXTP

HC Wainwright & Co. Reiterates Neutral on 60 Degrees

Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) has outperformed the market over the past 15 years by 1.85% on an annualized basis producing an average annual return of 13.57%. Currently, Johnson Controls Intl has a market capitalization of $56.41 billion. 
Buying $100 In JCI: If an investor had bought $100 of JCI stock 15 years ago, it would be worth $684.45 today based on a price of $84.45 for JCI at the time of writing.
<h3>Johnson Controls Intl's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699187_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Johnson Controls Intl 15 Years Ago Would Be Worth This Much Today

Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) has outperformed the market over the past 20 years by 1.26% on an annualized basis producing an average annual return of 9.59%. Currently, Crown Castle has a market capitalization of $44.95 billion. 
Buying $1000 In CCI: If an investor had bought $1000 of CCI stock 20 years ago, it would be worth $6,268.48 today based on a price of $103.43 for CCI at the time of writing.
<h3>Crown Castle's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699182_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Crown Castle Stock In The Last 20 Years

Total net revenues for the nine months ended September 30, amounted to EUR 200.1M, compared to EUR 179.8 M for the nine months ended September 30, ...

Galapagos:1st nine months FY24 net income EUR 103.5 vs. EUR 90.3 last year

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Galapagos (GLPG – Research Report). The company's shares opened to...

Galapagos (GLPG) Receives a Buy from TD Cowen

Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript

Galapagos NV 2024 Q3 - Results - Earnings Call Presentation

Galapagos NV ( ($GLPG) ) has released its Q3 earnings. Here is a breakdown of the information Galapagos NV presented to its investors. Galapagos NV...

Galapagos NV Sees Pipeline Growth Amid Financial Challenges

In a report released today, Emily Field from Barclays maintained a Hold rating on Galapagos (0JXZ – Research Report), with a price target of €30.00...

Barclays Keeps Their Hold Rating on Galapagos (0JXZ)

Jason Gerberry, an analyst from Bank of America Securities, reiterated the Sell rating on Galapagos (GLPG – Research Report). The associated price ...

Cautious Outlook for Galapagos: Sell Rating Amid Pipeline Uncertainties and Competitive Pressures

Deutsche Bank analyst Emmanuel Papadakis lowered the firm's price target on Galapagos (GLPG) to EUR 28 from EUR 30 and keeps a Hold rating on the s...

Galapagos price target lowered to EUR 28 from EUR 30 at Deutsche Bank

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Haleon PLC Sponsored ADR (HLN – Research Report), Insmed (INSM – ...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (HLN), Insmed (INSM) and Galapagos (GLPG)

Galapagos (GLPG) announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66th American Society of Hematology...

Galapagos to present data on CAR T-cell therapy candidates GLPG5101 and GLPG5201

GLPGF

INSM

Press Releases

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Galapagos receives transparency notification from FMR LLC

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Galapagos receives transparency notification from EcoR1 Capital

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Comments

Galapagos

매도 수량

Galapagos (NASDAQ:GLPG) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌